**TABLE S2.** Associations of serum albumin concentration with annual change* in eGFRcr in HIV-infected WIHS participants.

| | Unadjusted Estimate (95% CI) | P Value | Adjusted without ACR ** Estimate (95% CI) | P Value | Adjusted with ACR ** Estimate (95% CI) | P Value |
|---|---|---|---|---|---|---|
| **Continuous Predictors** | | | | | | |
| Serum Albumin (per -0.5 g/dL) | -0.59 (-0.79, -0.40) | p<0.001 | -0.52 (-0.71, -0.32) | p<.0001 | -0.48 (-0.68, -0.29) | p<0.001 |
| ACR (per doubling) | -0.22 (-0.33, -0.12) | p<0.001 | | | -0.24 (-0.34, -0.15) | p<0.001 |
| Baseline eGFRcr (per ↑10 ml/min) | -0.72 (-0.82, -0.62) | p<0.001 | -0.82 (-0.92, -0.72) | p<.0001 | -0.84 (-0.94, -0.75) | p<0.001 |
| **Dichotomized Predictors** | | | | | | |
| Serum Albumin < 3.8 g/dL | -0.64 (-1.02, -0.26) | p=0.0010 | -0.40 (-0.78, -0.016) | p=0.041 | -0.32 (-0.69, 0.063) | p=0.10 |
| ACR ≥ 30 mg/g | -0.86 (-1.43, -0.29) | p=0.0033 | | | -1.30 (-1.84, -0.76) | p<.0001 |
| Baseline eGFRcr<60 ml/min | 4.66 (3.71, 5.61) | p<.0001 | 4.65 (3.74, 5.57) | p<.0001 | 5.14 (4.21, 6.07) | p<.0001 |

* Results reported as estimated annual change (95% confidence interval) calculated from multivariable linear mixed models.
** Adjusted models control for age, race, HIV RNA, CD4, HCV, DM, ARV use, baseline eGFR, SBP, DBP, BMI, and study site. For ACR as a predictor instead of adjusting for ACR the full model adjusts for serum albumin concentration.
***ARV included current combination antiretroviral therapy (cART) use, current nucleoside reverse transcriptase inhibitor (NRTI) use, current non-nucleoside reverse transcriptase inhibitor (NNRTI) use, and current protease inhibitor (PI) use.